Enorama Pharma AB AI Stock Analysis
Want to see SE:ERMA full AI Analyst Report?
Enorama Pharma AB (ERMA) AI Stock Analysis
Enorama Pharma AB
(Nasdaq OMX AB:ERMA)
The stock's exceptionally low score is driven primarily by acute financial distress, including collapsing revenues, a massive equity deficit, and unsustainable cash burn. Compounding these fundamental risks are poor valuation metrics stemming from severe unprofitability and bearish short-term technical indicators.
Enorama Pharma AB (ERMA) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 49.08M
- Dividend Yield
- ―
- Average Volume (3M)
- 173.70K
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 0.80
- Revenue Growth
- -87.19%
- EPS Growth
- 29.58%
- Country
- Sweden
- Employees
- 4
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Pharmaceuticals
Enorama Pharma AB Business Overview & Revenue Model
Company Description
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based i...
Enorama Pharma AB Financial Statement Overview
Summary
The company is in severe financial distress, marked by plummeting revenues, monumental net losses, persistent cash burn, and a massive equity deficit. While debt-free, the fundamentals point to an urgent need for external capital.
Income Statement
10Very NegativeBalance Sheet
15Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.45M | 2.74M | 15.77M | 1.36M | 6.85M | 11.04M |
| Gross Profit | -42.79M | -61.78M | 3.70M | -3.90M | -616.00K | 2.13M |
| EBITDA | -54.13M | -61.65M | -20.41M | -40.18M | -37.22M | -25.56M |
| Net Income | -59.68M | -75.14M | -43.81M | -44.61M | -41.78M | -28.54M |
Balance Sheet | ||||||
| Total Assets | 6.95M | 8.26M | 15.89M | 34.38M | 48.72M | 50.93M |
| Cash, Cash Equivalents and Short-Term Investments | 2.10M | 3.04M | 2.08M | 6.15M | 4.14M | 12.20M |
| Total Debt | 0 | 0 | 0 | 436.00K | 1.91M | 3.79M |
| Total Liabilities | 57.39M | 31.71M | 8.09M | 14.85M | 17.20M | 29.58M |
| Stockholders Equity | -50.44M | -23.45M | 7.80M | 19.54M | 31.52M | 21.35M |
Cash Flow | ||||||
| Free Cash Flow | -53.05M | -59.26M | -35.70M | -41.35M | -32.96M | -31.99M |
| Operating Cash Flow | -53.05M | -59.26M | -35.70M | -41.35M | -32.96M | -30.16M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | -1.82M |
| Financing Cash Flow | 51.67M | 50.69M | 35.29M | 41.86M | 25.34M | 39.51M |
Enorama Pharma AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ERMA, the sentiment is Negative. The current price of 0.54 is below the 20-day moving average (MA) of 0.80, below the 50-day MA of 0.76, and below the 200-day MA of 0.56, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 45.84 is Neutral, neither overbought nor oversold. The STOCH value of 26.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ERMA.
Enorama Pharma AB Peers Comparison
Overall Rating
SE:ENZY46Neutral
SE:ONCO44Neutral
SE:ORX41Neutral
SE:ERMA39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 46Neutral | SEK 575.28M | -14.17 | ― | ― | -2.36% | 23.44% | |
| 44Neutral | SEK 747.11M | -2.75 | ― | ― | 65.37% | 43.28% | |
| 41Neutral | SEK 315.79M | -0.08 | -115.03% | ― | -97.68% | -83.26% | |
| 39Underperform | SEK 49.08M | -0.81 | ― | ― | -87.19% | 29.58% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:ERMA | Enorama Pharma AB | 0.54 | -2.26 | -80.71% | |
| SE:ORX | Orexo AB | 1.01 | -15.97 | -94.07% | |
| SE:ONCO | Oncopeptides AB | 1.68 | -3.29 | -66.19% | |
| SE:ENZY | Enzymatica AB | 2.40 | 0.45 | 23.08% | |
| SE:DICOT | Dicot Pharma AB | 0.21 | -0.11 | -34.18% | |
| SE:CINPHA | Cinclus Pharma Holding AB | 11.34 | -6.10 | -34.98% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
